Ardelyx AI Stock Analysis
Want to see ARDX full AI Analyst Report?
Ardelyx (ARDX) AI Stock Analysis
Ardelyx
(NASDAQ:ARDX)
The score is held back mainly by weak financial quality (continued losses, negative cash flow, and higher leverage) and a still-soft technical trend. Offsetting this, the latest earnings call was constructive with reaffirmed 2026 guidance, strong product revenue growth, and a stated path to profitability in 2027, but reimbursement and payer-related risks remain a notable overhang.
Ardelyx Key Performance Indicators (KPIs)
Revenue by SegmentSeparates revenue from product sales, licensing and collaboration payments, royalties, and milestones to show where the company’s money actually comes from. For Ardelyx, this reveals whether growth is driven by recurring commercial sales of its own drugs or by one‑time partner payments—steady product revenue points to sustainable commercial traction, while heavy reliance on milestones or licenses means earnings can be lumpy and more dependent on partner deals and development success.
Ardelyx’s revenue is now clearly powered by product sales while licensing and collaborative revenues are episodic—those big license spikes are one‑offs, not a repeatable base. The commercial ramp (expanded sales force, IPN and reimbursement hires) explains recent product momentum and underpins management’s back‑half‑weighted guidance, but lowered near‑term IBSRELA guidance and payer step‑edits are a tangible risk; sustaining growth and reaching the 2027 profitability path depend on reimbursement wins and continued prescription momentum, not more licensing windfalls.
Ardelyx (ARDX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $799.36M
- Dividend Yield
- ―
- Average Volume (3M)
- 4.43M
- Price to Earnings (P/E)
- -13.9
- Beta (1Y)
- 1.02
- Revenue Growth
- 17.57%
- EPS Growth
- 4.82%
- Country
- US
- Employees
- 489
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Ardelyx Business Overview & Revenue Model
Company Description
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both dome...
How the Company Makes Money
Ardelyx makes money primarily from sales of its commercial products and from collaboration-related income. Its key revenue stream is net product revenue generated by selling IBSRELA (for IBS-C) and XPHOZAH (for hyperphosphatemia in adults with CKD on...
Ardelyx Earnings Call Summary
The call was predominantly positive, supported by 19% total product revenue growth, 23% IBSRELA growth, strong demand trends, reaffirmed 2026 guidance, improved net loss, $285.3 million of liquidity, and ahead-of-schedule enrollment in the ACCEL Phase III trial. The main challenges were persistent payer friction, complex XPHOZAH reimbursement dynamics, gross-to-net erosion, recent prescription-data volatility, and continued operating investments. Management remained confident in execution and the path to profitability in 2027.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Ardelyx reaffirmed full year 2026 IBSRELA guidance of $350 million to $370 million, representing annual growth of more than 30% at the midpoint, and full year 2026 XPHOZAH revenue guidance of $110 million to $120 million; full year 2026 operating expenses are expected to be below $500 million, with profitability expected to occur in 2027, supported by a greater than 95% gross profit margin, while the company’s long-term view is achieving $1 billion in annual revenue for IBSRELA and it expects to report ACCEL top line results in the second half of 2027.
Ardelyx Financial Statement Overview
Summary
Strong revenue momentum and very high gross margins show improving fundamentals, but the company still has negative net income and negative operating/free cash flow. Rising leverage (elevated debt-to-equity) adds financial risk if the path to profitability is delayed.
Income Statement
58NeutralBalance Sheet
46NeutralCash Flow
41Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 468.22M | 407.32M | 333.62M | 124.46M | 52.16M | 10.10M |
| Gross Profit | 441.34M | 364.72M | 283.06M | 106.66M | 48.04M | 9.10M |
| EBITDA | -28.70M | -29.17M | -16.71M | -55.35M | -60.98M | -150.85M |
| Net Income | -55.47M | -61.60M | -39.14M | -66.07M | -67.21M | -158.16M |
Balance Sheet | ||||||
| Total Assets | 587.52M | 501.60M | 435.75M | 297.58M | 190.07M | 149.91M |
| Cash, Cash Equivalents and Short-Term Investments | 285.34M | 264.69M | 250.10M | 184.30M | 123.91M | 116.69M |
| Total Debt | 256.34M | 211.59M | 153.44M | 55.98M | 36.46M | 45.50M |
| Total Liabilities | 423.48M | 334.65M | 262.46M | 130.76M | 91.74M | 67.30M |
| Stockholders Equity | 164.05M | 166.95M | 173.29M | 166.82M | 98.33M | 82.62M |
Cash Flow | ||||||
| Free Cash Flow | -15.96M | -43.98M | -45.82M | -90.06M | -70.10M | -154.42M |
| Operating Cash Flow | -15.51M | -42.48M | -44.81M | -89.72M | -70.04M | -152.55M |
| Investing Cash Flow | -37.56M | -8.96M | -18.32M | -131.25M | 18.41M | 50.95M |
| Financing Cash Flow | 56.68M | 54.51M | 106.59M | 146.29M | 75.34M | 83.00M |
Ardelyx Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDX, the sentiment is Positive. The current price of 3.12 is above the 20-day moving average (MA) of 3.07, below the 50-day MA of 3.25, and below the 200-day MA of 5.06, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 51.97 is Neutral, neither overbought nor oversold. The STOCH value of 55.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARDX.
Ardelyx Risk Analysis
Ardelyx disclosed 53 risk factors in its most recent earnings report. Ardelyx reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksArdelyx Peers Comparison
Overall Rating
CRMD74Outperform
PHAT59Neutral
DMAC53Neutral
ARDX49Neutral
LXRX46Neutral
ENTA41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | $371.44M | 5.63 | 14.48% | ― | 92.48% | -64.25% | |
| 59Neutral | $430.85M | -5.14 | 29.66% | ― | 86.75% | 72.98% | |
| 53Neutral | $463.49M | -11.30 | -94.47% | ― | ― | -4.56% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $799.36M | -13.89 | -35.30% | ― | 17.57% | 4.82% | |
| 46Neutral | $765.80M | -11.84 | -38.44% | ― | -45.62% | 21.16% | |
| 41Neutral | $253.10M | -3.50 | -64.32% | ― | -3.56% | 38.76% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ARDX | Ardelyx Inc | 3.12 | -2.43 | -43.78% | |
| CRMD | Cormedix Inc. | 4.50 | -5.22 | -53.70% | |
| LXRX | Lexicon Pharmaceuticals | 1.72 | 0.40 | 30.30% | |
| ENTA | Enanta Pharmaceuticals | 8.23 | -3.90 | -32.15% | |
| DMAC | Diamedica Therapeutics | 8.59 | 1.37 | 18.98% | |
| PHAT | Phathom Pharmaceuticals, Inc. | 5.30 | -9.06 | -63.09% |
Ardelyx Corporate Events
Ardelyx Reports Third-Quarter Revenue Growth and Narrowed Loss
PositiveOn November 3, 2026, Ardelyx reported third-quarter product revenue of $125.5 million, up 19% year over year. IBSRELA revenue rose 23% to $96.3 million, while XPHOZAH revenue increased 7% to $29.2 million, reflecting higher demand, writers and prescr...
Ardelyx Chief Commercial Officer Announces Upcoming Resignation
NeutralOn August 11, 2026, Ardelyx, Inc. announced that Chief Commercial Officer Eric Foster had notified the company of his decision to resign, effective August 28, 2026. The departure, which was to allow Foster to pursue a new role at a pre-commercial com...
Ardelyx Updates Outlook Amid Q2 Growth and Recalibration
NeutralArdelyx reported that in the second quarter ended June 30, 2026, total product revenue rose 31% year over year to $118.1 million, driven by IBSRELA sales of $86.2 million and XPHOZAH sales of $31.9 million, while cash and investments reached $281.8 m...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
